Patterns of Care Among Australian Cohort of Patients With Advanced RCC Receiving Sutent
Phase of Trial: Phase IV
Latest Information Update: 03 Apr 2015
Price : $35 *
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 18 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Dec 2013 Planned end date changed from 1 Nov 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 09 Aug 2013 New trial record